Affinity and cross-reactivity engineering of CTLA4-Ig to modulate T cell costimulation

Journal of Immunology

Volumn 189, Issue 9, 2012, Pages 4470-4477

  Xu, Zhenghai ^a   Juan, Veronica ^a,b   Ivanov, Alexander ^a   Ma, Zhiyuan ^a   Polakoff, Dixie ^a   Powers, David B ^a   DuBridge, Robert B ^a,c   Wilson, Keith ^a   Akamatsu, Yoshiko ^a  

^a ABBOTT LABORATORIES   (United States)

^b AvidBiotics   (United States)

^c Full Spectrum Genetics Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; CD86 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY;

AMINO ACID SUBSTITUTION; ARTICLE; BINDING AFFINITY; CD4+ T LYMPHOCYTE; COMPLEX FORMATION; CONTROLLED STUDY; CRYSTAL STRUCTURE; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; LIGAND BINDING; MUTATIONAL ANALYSIS; POINT MUTATION; PRIORITY JOURNAL; PROTEIN ENGINEERING; PYROSEQUENCING; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

ANIMALS; ANTIGENS, CD80; ANTIGENS, CD86; ARTHRITIS, RHEUMATOID; CHO CELLS; CRICETINAE; CRICETULUS; CROSS REACTIONS; GENES, SYNTHETIC; HEK293 CELLS; HUMANS; IMMUNOCONJUGATES; JURKAT CELLS; LYMPHOCYTE ACTIVATION; PEPTIDE LIBRARY; PLASMIDS; PROTEIN BINDING; T-LYMPHOCYTE SUBSETS;

EID: 84867908105     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1201813     Document Type: Article

References (29)

1. Walunas, T. L., D. J. Lenschow, C. Y. Bakker, P. S. Linsley, G. J. Freeman, J. M. Green, C. B. Thompson, and J. A. Bluestone. 1994. CTLA-4 can function as a negative regulator of T cell activation. Immunity 1: 405-413.
2. Bluestone, J. A., E. W. St Clair, and L. A. Turka. 2006. CTLA4Ig: bridging the basic immunology with clinical application. Immunity 24: 233-238.
3. Moreland, L., G. Bate, and P. Kirkpatrick. 2006. Abatacept. Nat. Rev. Drug Discov. 5: 185-186. (Pubitemid 43336031)
4. Kirk, A. D., D. M. Harlan, N. N. Armstrong, T. A. Davis, Y. Dong, G. S. Gray, X. Hong, D. Thomas, J. H. Fechner, Jr., and S. J. Knechtle. 1997. CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates. Proc. Natl. Acad. Sci. USA 94: 8789-8794. (Pubitemid 27335118)
5. Levisetti, M. G., P. A. Padrid, G. L. Szot, N. Mittal, S. M. Meehan, C. L. Wardrip, G. S. Gray, D. S. Bruce, J. R. Thistlethwaite, Jr., and J. A. Bluestone. 1997. Immunosuppressive effects of human CTLA4Ig in a non-human primate model of allogeneic pancreatic islet transplantation. J. Immunol. 159: 5187-5191. (Pubitemid 127470041)
6. Wekerle, T., and J. M. Grinyó. 2012. Belatacept: from rational design to clinical application. Transpl. Int. 25: 139-150.
7. Larsen, C. P., T. C. Pearson, A. B. Adams, P. Tso, N. Shirasugi, E. Strobert, D. Anderson, S. Cowan, K. Price, J. Naemura, et al. 2005. Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties. Am. J. Transplant. 5: 443-453. (Pubitemid 40313335)
8. Fowler, D. M., C. L. Araya, S. J. Fleishman, E. H. Kellogg, J. J. Stephany, D. Baker, and S. Fields. 2010. High-resolution mapping of protein sequence-function relationships. Nat. Methods 7: 741-746.
9. Akamatsu, Y., K. Pakabunto, Z. Xu, Y. Zhang, and N. Tsurushita. 2007. Whole IgG surface display on mammalian cells: application to isolation of neutralizing chicken monoclonal anti-IL-12 antibodies. J. Immunol. Methods 327: 40-52. (Pubitemid 47444311)
10. Peach, R. J., J. Bajorath, W. Brady, G. Leytze, J. Greene, J. Naemura, and P. S. Linsley. 1994. Complementarity determining region 1 (CDR1)- and CDR3-analogous regions in CTLA-4 and CD28 determine the binding to B7-1. J. Exp. Med. 180: 2049-2058. (Pubitemid 24351586)
11. Schwartz, J. C., X. Zhang, A. A. Fedorov, S. G. Nathenson, and S. C. Almo. 2001. Structural basis for co-stimulation by the human CTLA-4/B7-2 complex. Nature 410: 604-608. (Pubitemid 32267207)
12. Stamper, C. C., Y. Zhang, J. F. Tobin, D. V. Erbe, S. Ikemizu, S. J. Davis, M. L. Stahl, J. Seehra, W. S. Somers, and L. Mosyak. 2001. Crystal structure of the B7-1/CTLA-4 complex that inhibits human immune responses. Nature 410: 608-611. (Pubitemid 32267208)
13. Cox, G. N., D. Pratt, D. Smith, M. J. McDermott, and R. W. Vanderslice. 1999. Refolding and characterization of recombinant human soluble CTLA-4 expressed in Escherichia coli. Protein Expr. Purif. 17: 26-32. (Pubitemid 29504374)
14. Croft, M., and C. Dubey. 1997. Accessory molecule and costimulation requirements for CD4 T cell response. Crit. Rev. Immunol. 17: 89-118. (Pubitemid 27068809)
15. Linsley, P. S., J. L. Greene, W. Brady, J. Bajorath, J. A. Ledbetter, and R. Peach. 1994. Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors. Immunity 1: 793-801.
16. Ikemizu, S., R. J. Gilbert, J. A. Fennelly, A. V. Collins, K. Harlos, E. Y. Jones, D. I. Stuart, and S. J. Davis. 2000. Structure and dimerization of a soluble form of B7-1. Immunity 12: 51-60. (Pubitemid 30069214)
17. Collins, A. V., D. W. Brodie, R. J. Gilbert, A. Iaboni, R. Manso-Sancho, B. Walse, D. I. Stuart, P. A. van der Merwe, and S. J. Davis. 2002. The interaction properties of costimulatory molecules revisited. Immunity 17: 201-210. (Pubitemid 35245962)
18. Zhang, X., J. C. Schwartz, S. C. Almo, and S. G. Nathenson. 2003. Crystal structure of the receptor-binding domain of human B7-2: insights into organization and signaling. Proc. Natl. Acad. Sci. USA 100: 2586-2591. (Pubitemid 36297542)
19. Salomon, B., and J. A. Bluestone. 2001. Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation. Annu. Rev. Immunol. 19: 225-252. (Pubitemid 32368035)
20. + B cells in active multiple sclerosis and reversal by interferon β-1b therapy. J. Clin. Invest. 99: 2664-2671.
21. Karandikar, N. J., C. L. Vanderlugt, J. A. Bluestone, and S. D. Miller. 1998. Targeting the B7/CD28:CTLA-4 costimulatory system in CNS autoimmune disease. J. Neuroimmunol. 89: 10-18. (Pubitemid 28389570)
22. Bîrsan, T., B. Hausen, J. P. Higgins, R. W. Hubble, J. Klupp, M. Stalder, A. Celniker, S. Friedrich, R. M. O'Hara, and R. E. Morris. 2003. Treatment with humanized monoclonal antibodies against CD80 and CD86 combined with sirolimus prolongs renal allograft survival in cynomolgus monkeys. Transplantation 75: 2106-2113. (Pubitemid 36793301)
23. Kirk, A. D., D. K. Tadaki, A. Celniker, D. S. Batty, J. D. Berning, J. O. Colonna, F. Cruzata, E. A. Elster, G. S. Gray, R. L. Kampen, et al. 2001. Induction therapy with monoclonal antibodies specific for CD80 and CD86 delays the onset of acute renal allograft rejection in non-human primates. Transplantation 72: 377-384. (Pubitemid 32769620)
24. Saegusa, K., N. Ishimaru, K. Yanagi, N. Haneji, M. Nishino, M. Azuma, I. Saito, and Y. Hayashi. 2000. Treatment with anti-CD86 costimulatory molecule prevents the autoimmune lesions in murine Sjögren's syndrome (SS) through up-regulated Th2 response. Clin. Exp. Immunol. 119: 354-360. (Pubitemid 30073042)
25. Stephens, L. A., and T. W. Kay. 1995. Pancreatic expression of B7 co-stimulatory molecules in the non-obese diabetic mouse. Int. Immunol. 7: 1885-1895. (Pubitemid 26003695)
26. Lenschow, D. J., S. C. Ho, H. Sattar, L. Rhee, G. Gray, N. Nabavi, K. C. Herold, and J. A. Bluestone. 1995. Differential effects of anti-B7-1 and anti-B7-2 monoclonal antibody treatment on the development of diabetes in the nonobese diabetic mouse. J. Exp. Med. 181: 1145-1155.
27. Jain, N., H. Nguyen, C. Chambers, and J. Kang. 2010. Dual function of CTLA-4 in regulatory T cells and conventional T cells to prevent multiorgan autoimmunity. Proc. Natl. Acad. Sci. USA 107: 1524-1528.
28. + regulatory T cells. J. Immunol. 171: 3348-3352.
29. Grohmann, U., C. Orabona, F. Fallarino, C. Vacca, F. Calcinaro, A. Falorni, P. Candeloro, M. L. Belladonna, R. Bianchi, M. C. Fioretti, and P. Puccetti. 2002. CTLA-4-Ig regulates tryptophan catabolism in vivo. Nat. Immunol. 3: 1097-1101. (Pubitemid 35363664)